Scientists identify key protein modification required for Zika virus spread

Zika virus and dengue virus spread through mosquito populations with alarming efficiency, causing everything from silent infections to severe birth defects and neurological damage. The reason these viruses are so effective at colonizing human cells and evading immune defenses has long been partially mysterious—but a team of researchers has now identified a crucial molecular mechanism that the virus depends on to survive and replicate.

The key lies in a viral protein called NS1, which the virus produces inside infected cells. This protein exists in two forms: some of it stays anchored to cell membranes, while some gets secreted into the bloodstream. NS1 is a multitasker for the virus—it helps the virus replicate its genetic material, it helps the virus hide from the immune system, and it contributes to the tissue damage that makes the infection dangerous. Understanding how NS1 works has therefore become a priority for researchers seeking new ways to stop these viruses.

Scientists at Radboud University Medical Center infected two types of human cells—liver cells and neural progenitor cells—with a specially engineered Zika virus that carried a molecular tag on its NS1 protein. Using mass spectrometry, they identified every protein that NS1 interacted with inside the cell. The results revealed a pattern: NS1 was binding to prolyl hydroxylases, a family of enzymes that modify other proteins by adding hydroxyl groups to proline amino acids. The mass spectrometry data also showed that NS1 itself contained the chemical signatures of having been modified this way. This suggested that prolyl hydroxylation—the addition of these hydroxyl groups—was happening to NS1 and might be essential for the virus.

To test this hypothesis, the researchers chemically blocked prolyl hydroxylases and watched what happened. The NS1 protein failed to reach the cell membrane where it needs to be. Viral RNA levels dropped sharply. The amount of infectious virus particles produced plummeted. The modification was clearly necessary for the virus to spread effectively. The team then used genetic engineering to mutate specific proline residues in NS1—first the one at position 281, then the one at position 267. Changing the proline at position 281 prevented NS1 from being secreted, though the virus could still replicate inside cells. Changing the proline at position 267 had a more dramatic effect: it so severely disrupted NS1 that the virus could barely replicate at all. Remarkably, when researchers allowed the mutated virus to grow for just a single passage through cells, the mutation reverted back to the original sequence—the virus essentially corrected itself because the mutation was so damaging.

These findings establish prolyl hydroxylation as a non-negotiable step in the Zika virus life cycle. The virus cannot spread without it. This opens a therapeutic avenue: drugs that inhibit prolyl hydroxylases might be able to stop Zika replication without harming human cells, since human cells use these enzymes for their own purposes but can tolerate some disruption. The same mechanism likely applies to dengue virus and other related mosquito-borne viruses that share similar NS1 proteins. The research suggests that targeting this single post-translational modification could disrupt multiple viruses at once—a rare opportunity in antiviral drug development.